4 Results for "

pY1068

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "pY1068" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-124674A
CAS No.: 2126136-98-7
Purity:  98.07%
Research Areas:  

Cancer

CCT365623 hydrochloride is an orally active lysyl oxidase (LOX) inhibitor, with an IC50 of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties .
loading...
    loading...
Cat. No.: HY-176938A
Target:  

EGFR PhosTACs

Research Areas:  

Cancer

iAfaPhos1 is a FKBP12F36V epimer ligand. iAfaPhos1 leads to reduced dephosphorylation of EGFR at pY1068 and pY845 sites. iAfaPhos1 has anticancer activity against non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-176938
Research Areas:  

Cancer

AfaPhos1 is a new, Afatinib (HY-10261)-based EGFR PhosTAC. AfaPhos1 induces EGFR dephosphorylation at both pY1068 and pY845. AfaPhos1 induces Apoptosis. AfaPhos1 has anticancer activity against non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-17654
CAS No.: 1429497-30-2
Target:  

EGFR mTOR

Research Areas:  

Cancer

BIEGi-1 is an EGFR inhibitor. BIEGi-1 effectively disrupts the EGFR-Rheb interaction in cells. BIEGi-1 robustly inhibits EGFR kinase activity (reduces p-Y1068-EGFR) as well as mTORC1 activation (reduces p-T389-S6K1) in EGFR-mutant cells. BIEGi-1 shows strong antiproliferative effects on EGFR-mutant PC9 and HCC827 cells with IC50 values of 17 nM and 20 nM, respectively. BIEGi-1 can be used for the study of cancers harboring EGFR mutations, such as non-small cell lung cancer (NSCLC) .
loading...
    loading...